Caidya vs Schrödinger
Side-by-side comparison of AI visibility scores, market position, and capabilities
Caidya is a global mid-sized CRO formed from the merger of dMed Global and Clinipace; operates in 20+ countries across 50+ regions; raised $165M from Rubicon Founders in January 2025;
About
Caidya is a global, full-service contract research organization (CRO) formed in 2021 through the merger of dMed Global, a Shanghai-based clinical research firm, and Clinipace Incorporated, a North Carolina-based CRO. The combined entity rebranded as Caidya with a mission to "liberate clinical research" by providing more personalized, knowledge-driven CRO services to biopharmaceutical innovators developing breakthrough therapies for patients with unmet medical needs. Headquartered in Raleigh, North Carolina, Caidya operates across more than 20 countries with study execution capabilities spanning more than 50 countries and regions — including deep expertise in the Americas, Europe, and Asia-Pacific, particularly Mainland China.
Physics-based molecular simulation platform used by 1,700+ organizations. Q3 2025 software revenue up 54% YoY; $150M Novartis collaboration signed in early 2025.
About
Schrödinger was founded in 1990 by Richard Friesner and David Pearlman in New York City, building physics-based computational methods for molecular simulation. For over 30 years the company has developed the industry-leading molecular modeling suite used by academic researchers, biotech startups, and large pharmaceutical companies to predict molecular properties, optimize lead compounds, and design drugs with greater precision than traditional empirical approaches.\n\nSchrödinger's platform—spanning FEP+ (free energy perturbation), Glide docking, WaterMap, and machine learning-enhanced property prediction—is used by over 1,700 organizations across pharma, biotech, and materials science. In early 2025, the company signed a landmark $150 million upfront collaboration with Novartis for multi-target drug discovery with potential milestones exceeding $2.3 billion. Software revenue grew 54% year-over-year in Q3 2025 as pharmaceutical companies accelerated adoption of computational-first drug discovery. Schrödinger also operates a proprietary drug pipeline, with SGR-1505 (MALT1 inhibitor) in Phase 1 for B-cell malignancies.\n\nSchrödinger occupies a unique hybrid position—part software platform, part drug discovery company—and is a benchmark of the AI/physics-based drug discovery movement. The company is publicly traded (SDGR) and is recognized as an essential tool for the modern small-molecule drug discovery workflow.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.